Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority
Press release content from Business Wire. The AP news staff was not involved in its creation. Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority December 18, 2020 GMT SAN FRANCISCO & NESS ZIONA, Israel--(BUSINESS WIRE)--Dec 18, 2020-- Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotec...
Source: apnews.com